1030 Immunology - Columbus Chapter of the Oncology Nursing

3/16/2015
Cancer Immunotherapy
Review: Oncology
Perspective
Paul Monk, MD
Associate Professor
Division Medical Oncology
James Cancer Hospital, The Ohio State University
26th Annual Spring Conference 2015_Columbus
Chapter of the Oncology Nursing Society:
Kaleidoscope of Oncology Care
March 27, 2015
1
Speaker Disclosures
•
•
•
•
Consultant and speaker for Dendreon
Consultant for Bayer
Consultant and speaker for Sanofi-Aventis
Research support from Prometheus
2
Learning Objectives
• Review the evidence supporting the immune system’s
role in cancer and the characteristics of an immune
response
• Describe several mechanisms of immunotherapy
• Discuss treatment considerations for cancer
immunotherapy
3
1
3/16/2015
Talk Outline
Immune System’s Role in Cancer
Immunotherapy Landscape
Clinical Considerations of Immunotherapy
State of Immunotherapy
4
Cancer Pathogenesis: Formerly
Characterized by 6 Hallmarks
Evading
growth
suppressors
Sustaining
proliferative
signaling
Activating
invasion and
metastasis
Hallmarks
of Cancer
Pathogenesis
(2000)
Resisting
cell death
Enabling
replicative
immortality
Inducing
angiogenesis
Hanahan D, Weinberg RA. Cell. 2000;100(1):57-70.
5
Cancer Pathogenesis: Immune Evasion
Now Recognized as a Hallmark
Avoiding
immune
destruction
Deregulating
cellular
energetics
Evading
growth
suppressors
Activating
invasion and
metastasis
Hallmarks
of Cancer
Pathogenesis
(2011)
Sustaining
proliferative
signaling
Enabling
replicative
immortality
Inducing
angiogenesis
Resisting
cell death
Hanahan D, Weinberg RA. Cell. 2011;144(5):646-674.
6
2
3/16/2015
Increased Incidence of Cancer in
Immunocompromised Individuals
• Malignant tumors develop in individuals with compromised
immune systems1-4
Tumor / cancer risk in transplant patients compared to general population 1-3
Non-melanoma skin cancer
Non-Hodgkin’s lymphoma
Kaposi’s sarcoma
Kidney cancer
Melanoma
Vulvovaginal cancer
Cervical cancer
Hepatobiliary cancer
Leukemia
Bladder cancer
Testicular cancer
Breast cancer
Ovarian cancer
Pancreatic cancer
Esophageal cancer
Stomach cancer
Prostate cancer
Lung cancer
Colon cancer
20-fold and beyond
15-fold
8-fold
5-fold
3-fold
2-fold
0
5
10
15
Fold-increase in tumor/cancer risk
1. Kasiske BL, Wang C, et al. Am J Transplant. 2004;4(6):905-913.
2. Le Mire L, Wojnarowska F, et al. Br J Dermatol. 2006;154(3):472-477.
20
3. Herrero JI. Liver Transpl. 2009;15(suppl 2):S90-S94.
4. Abbas AK, Lichtman AH. Basic Immunology. 3rd ed. 2011.
7
Immune Cells Within Tumors Predicts
Overall Survival
• T-cell infiltration within tumors is associated with overall
survival (OS) in patients with different cancers1,2
Kaplan-Meier Curve for OS in
Advanced Ovarian Cancer1
P<0.001
a
a) T cells
infiltrating
tumor cells
b
b) No intratumoral
T cells detected:
T cells restricted
to tissue
surrounding
tumor
100
OS (%)
75
Intratumoral T cells (n=102)
Median OS = 50.3 months
50
25
n=102
No intratumoral T cells (n=72)
Median OS = 18 months
0
0 12 24 36 48 60 72 84 96 108 120 132
Month
Adapted with permission from Zhang L, Coukos G, et al.
1. Zhang L, Coukos G, et al. N Engl J Med. 2003;348(3):203-213.
2. Galon J, Pagès F, et al. Science. 2006;313(5795):1960-1964.
8
Immunotherapy Proven Effective in Cancer
• Therapies that engage the immune system have been
shown to improve patient survival in randomized,
phase 3 cancer trials1-3
• Immunotherapies (cytokines, checkpoint inhibitors,
therapeutic vaccines, monoclonal antibodies) have
been approved by the FDA to treat certain cancers4
1.
2.
3.
4.
Robert C, Wolchok JD, et al. N Engl J Med. 2011;364(26):2517-2526.
Hodi FS, Urba WJ, et al. N Engl J Med. 2010;363(8):711-723.
Kantoff PW, Schellhammer PF, et al. N Engl J Med. 2010;363(5):411-422.
Mellman I, Dranoff G, et al. Nature. 2011;480 (7378): 480-489.
9
3
3/16/2015
Dynamics Between Cancer
and the Immune System
• In a dynamic process, the immune system
can either
– Block tumor growth, development, and survival
– Allow tumor outgrowth
Immune
Protection
Immune
Evasion
10
Dunn GP, Schreiber RD, et al. Nat Rev Immunol. 2006;6(11):836-848.
Dynamic Process Described by 3 Phases
• The 3 E’s
– Elimination
– Equilibrium
– Escape
11
Dunn GP, Schreiber RD, et al. Nat Rev Immunol. 2006;6(11):836-848.
Elimination: Immune System
Eradicates Cancer Cells1
Immune
Protection
Immune
Evasion
• A natural process involved with early disease2
Immune cells
Abnormal cells/tissue
Normal cells/tissue
Adapted from Dunn GP, Schreiber RD, et al.1
1. Dunn GP, Schreiber RD, et al. Nat Rev Immunol. 2006;6(11):836-848.
2. Trinchieri G. In: Cancer: Principles & Practice of Oncology. 9th ed. 2011.
12
4
3/16/2015
Equilibrium: Immune System
Controls Cancer Cells1
Immune
Protection
Immune
Evasion
• Occurs with later stage tumors2
• Represents a balanced “dynamic” between the immune system
and cancer1,2
Immune cells
Abnormal cells / tissue
outgrowth controlled
Adapted from Dunn GP, Schrieber RD, et al.1
1. Dunn GP, Schreiber RD, et al. Nat Rev Immunol. 2006;6(11):836-848.
2. Trinchieri G. In: Cancer: Principles & Practice of Oncology. 9th ed. 2011.
13
Immune
Protection
Escape: Cancer Cells Evade
Immune System
Immune
Evasion
• Tumor cell variants grow, resulting in progressive disease
Immune cells
Abnormal cells / tissue
Abnormal cells / tissue
continue to replicate
Adapted from Dunn GP, Schreiber RD, et al.
Dunn GP, Schreiber RD, et al. Nat Rev Immunol. 2006;6(11):836-848.
14
Key Components Involved in the
Immune Response
• Antigens
– Molecules produced by microbes or foreign agents that bind to
T cells and antibodies
• Antigen presenting cells (APCs)
– Identify and uptake foreign antigens
– Present them to T cells
• T cells
– Activated by APCs
– Recognize and destroy cells containing foreign antigen
• B cells
– Produce antibodies specific to foreign antigens
Abbas AK, Lichtman AH. Basic Immunology. 3rd ed. 2011.
15
5
3/16/2015
Initiation of Immune Response:
Key Components
Antigen
fragments
Antigen
Naive
T-cell
Antigen
receptors
Activated
T-cell
Antigen
presenting
cell (APC)
Antigen
recognition
Effector cells:
1. Activate other
immune cells
2. Kill “target cells”
Memory cells:
1. Circulate for months  years
2. Ready to rapidly respond to
same antigen again
Activated
APC
T-cell
interaction
T-cell
activation
Activation
Replication of
antigen-specific
T-cells
T-cells become
specialized
Lymphoid Organs
Adapted from Abbas AK, Lichtman AH.
Peripheral Tissues
Abbas AK, Lichtman AH. Basic Immunology. 3rd ed. 2011.
16
Features of an Effective
Immune Response1,2
• Specificity
• Trafficking
• Adaptability
• Target elimination
• Durability (immune memory)
1. Abbas AK, Lichtman AH. Basic Immunology. 3rd ed. 2011.
2. Drake CG. Nat Rev Immunol. 2010;10(8);580-593.
17
Immune Response: Specificity
• Ability of immune cells to identify and target a
specific antigen1
In type 1 diabetes, T cells recognize and destroy only β cells2
Pancreatic islets of
Langerhans
(normal)
α cells
(black)
Pancreatic islets of
Langerhans
(type 1 diabetes)
α cells
(black)
β cells
(brown)
Reprinted with permission from Irene Visintin, MD.
1. Abbas AK, Lichtman AH. Basic Immunology. 3rd ed. 2011.
2. Murphy K. Janeway’s Immunobiology. 8th ed. 2012.
T cell
infiltration
18
6
3/16/2015
Immune Response: Trafficking
Injection of
naive T cells
• Ability of activated
immune system cells
to migrate to particular
antigens throughout
the body1-3
• In this example,
activated T cells were
mobilized to areas
containing antigen1
Injection of
activated T cells
Spleen
Activated
T cells
mobilized
to antigen
Testes
1. Reinhardt RL, Jenkins MK, et al. Nature. 2001;410(6824):101-105.
2. Drake CG. Nat Rev Immunol. 2010;10(8):580-593.
3. Abbas AK, Lichtman AH. Basic Immunology. 3rd ed. 2011.
Reprinted with permission from Reinhardt RL, Jenkins MK, et al. 1
19
Immune Response: Adaptability
• Allows for a broader immune response1
(eg, immune response to additional antigens2)
Tumor
Activated
T cell
Tumor
PAP
APC
APC
Adapted from Gulley JL. Hum Vaccin Immunother. 2013;9(1):1-3.
Naive T cell
PSMA, prostate-specific membrane antigen; PSCA, prostate stem cell antigen; PAP, prostatic acid phosphatase; MUC-1, mucin-1.
1. Abbas AK, Lichtman AH. Basic Immunology. 3rd ed. 2011.
2. Nesslinger NJ, Gulley JL, et al. Clin Cancer Res. 2010;16(15):4046-4056.
20
Immune Response: Target Elimination
• Ability of immune cells to destroy their target (eg, cancer cells)1,2
– Usually via induction of apoptosis3
Target cell death3:
Scanning Electron Micrograph showing T cells inducing
a target cell to undergo apoptosis
T cell
T Cell
Apoptotic Bodies
Target Cell
(eg, cancer cell)
Courtesy of sciencesource.com
1. Abbas AK, Lichtman AH. Basic Immunology. 3rd ed. 2011.
2. Boissonnas A, Amigorena S, et al. J Exp Med. 2007;204(2):345-356.
3. Trapani JA, Smyth MJ. Nat Rev Immunol. 2002;2(10):735-747.
21
7
3/16/2015
Immune Response: Durability
(Immune Memory)
• Ability of immune system to recognize an antigen to
which it has previously been exposed and provide
long-lasting protection against it1
Shown is the durable virus-specific T-cell response after
smallpox vaccination2
Volunteers with CD4+ T-Cell Memory After One
Smallpox Vaccination
20-30 years
31-50 years
51-75 years
0
20
1. Abbas AK, Lichtman AH. Basic Immunology. 3rd ed. 2011.
2. Hammarlund E, Slifka MK, et al. Nat Med. 2003;9(9):1131-1137.
40
60
Percentage
80
100
22
Program Agenda
Immune System’s Role in Cancer
Immunotherapy Landscape
Clinical Considerations of Immunotherapy
State of Immunotherapy
23
Immunotherapy
Definition1
• Treatment to boost or restore the ability of the immune
system to fight cancer, infections, and other diseases
Examples in cancer2
•
•
•
•
Monoclonal antibodies
Cytokines
Checkpoint inhibitors
Therapeutic vaccines
1. National Cancer Institute. Cancer terms. http://www.cancer.gov/dictionary/?print=1&cdrid=45729. Accessed October 5, 2012.
2. Mellman I, Dranoff G, et al. Nature. 2011;480(7378):480-489.
24
8
3/16/2015
The Renaissance of Immunotherapy1-5
1890s
1st CA
vaccine
developed
(Coley)
Enthusiasm Phase
Skepticism Phase
1978-1985
1985-1997
1976
1st study
with BCG in
bladder CA
1997-
1986
IFN-α
1985
(cytokine)
1st study with approved for
adoptive T-cell
CA
transfer in CA
1992
2010
IL-2 (cytokine)
approved
for CA
1st cellular
immunotherapy
approved for CA
1990s
1978
1973
Discovery
of the
dendritic cell
(Steinman)
Renaissance Phase
Discovery
of tumor
specific
mABs
Discovery of
role of
checkpoint
inhibitors
in CA
1997
1st mAB
approved
for CA
2011
1st checkpoint
inhibitor
approved
for CA
Adapted with permission from Lesterhuis WJ, et al2 and Kirkwood JM, et al. J Clin Oncol. 2008;26(20):3445-3455.
BCG, Bacille Calmette-Guerin; mABs, monoclonal antibodies; CA, cancer; IFN-α, interferon alpha; IL-2, interleukin-2
3. Krummel MF, Allison JP. J Exp Med. 1995;182(2):459-465.
1. Kirkwood JM, Ferrone S, et al. CA Cancer J Clin. 2012;62(5):309-335.
4. Lotze M. In: Cancer: Principles & Practice of Oncology. 9th ed. 2011.
2. Lesterhuis WJ, Punt CJ, et al. Nat Rev Drug Discov. 2011;10(8):591-600.
5. Leget GA, Czuczman MS. Curr Opin Oncol. 1998;10(6):548-551. 25
Types of Immunotherapy
• Cytokines
• Monoclonal antibodies
• Checkpoint inhibitors
• Therapeutic cancer vaccines
26
Mellman I, Dranoff G, et al. Nature. 2011;480(7378):480-489.
Cytokines
• Proteins that are naturally
secreted by immune system
cells1
IL-2 Stimulation of T-cell Proliferation2
IL2 Receptor
• Mechanism of action2
– Interleukin-2 (IL-2) stimulates
T-cell proliferation
• Examples2
– Interleukins, interferons
• Efficacy3
– High dose IL-2 administration
resulted in long term disease-free
survival in patients with melanoma
and renal cell carcinoma
1. Abbas AK, Lichtman AH. Basic Immunology. 3rd ed. 2011.
2. Bachmann MF, Oxenius A. EMBO Rep. 2007;8(12):1142-1148.
3. Lotze M. In: Cancer: Principles & Practice of Oncology. 9th ed. 2011.
Cell
Proliferation
27
9
3/16/2015
Cytokines
•
Interferon-α (IFN-α): “the control”
– Median PFS: 4.7 mo
– Median OS: 13 mo
•
High dose Interleukin (IL-2)
– Response rate: 15-20%
– 5-7% durable CRs
– NCI 1986-2006
Median Overall Survival
CR: Not reached
PR: 39.1 mo
No response: 15.1 mo
Toxicity!
Rosenberg, SA. Ann Surg 1998
Yang, J. C. et al. J Clin Oncol; 21:3127-3132
2003
28
Monoclonal Antibodies (mABs)
• Mechanism of action1,2
Potential mechanisms of mABs in cancer
– Differs between agents
– Bind to their specific target
antigen ultimately causing
cell death
• Efficacy3-7
– Improved overall and
progression-free survival
(PFS) in randomized, phase 3
clinical trials in breast cancer,
colorectal cancer, leukemia,
and head and neck cancer
1.
2.
3.
4.
Cheson BD, Leonard JP. N Engl J Med. 2008;359(6):613-626.
Weiner LM, Wang S. Nat Rev Immunol. 2010;10(5):317-327.
Slamon DJ, Norton L, et al. N Engl J Med. 2001;344(11):783-792.
Curran D, Bonner JA, et al. J Clin Oncol. 2007;25(16):2191-2197.
T cell
Cytokine-mAb
Tumor
cell
ToxinmAb
Drug-mAb
Receptor
Tumor cell death
Adapted from Kirkwood JM, Ferrone S, et al.
CA Cancer J Clin. 2012;62(5):309-335.
5. Vermorken JB, Hitt R, et al. N Engl J Med. 2008;359(11):1116-1127.
6. Jonker DJ, Moore MJ, et al. N Engl J Med. 2007;357(20):2040-2048.
7. Robak T, Moiseev SI, et al. J Clin Oncol. 2010;28(10):1756-1765.
29
Checkpoint Inhibitors
• Mechanism of action1,2
– Block immune checkpoints
that regulate T cell
activation/function
Activated
APC
• Examples1,2
– CTLA-4 and PD1
CTLA4
receptor
Naive
T cell
CTLA4
antibodies
• Efficacy3-6
– Extends overall survival in
certain metastatic diseases
– A significant effect on PFS not
consistently observed
PD1
receptor
PD1
antibodies
Adapted with permission from Sharma P, Allison JP, et al. 2
CTLA-4, cytotoxic T lymphocyte-associated antigen 4; PD1, programmed cell death protein 1
1.
2.
3.
4.
5. Brahmer JR, Wigginton JM, et al. N Engl J Med. 2012;366(26):
Pardoll D. Nat Rev Cancer. 2012;12(4):252-264.
2455-2465.
Sharma P, Allison JP, et al. Nat Rev Cancer. 2011;11(11):805-812.
6. Topalian SL, Sznol M, et al. N Engl J Med. 2012;366(26):
Hodi FS, Urba WJ, et al. N Engl J Med. 2010;363(8):711-723.
2443-2454.
Robert C, Wolchok JD, et al. N Engl J Med. 2011;364(26):2517-2526.
30
10
3/16/2015
Anti CTLA therapy. Ipilimumab in melanoma
Hodi FS et al. N Engl J Med 2010;363:711-723
Hodi FS et al. N Engl J Med
2010;363:711-723
31
Melanoma
• pembrolizumab (Keytruda, MK-3475)
– First PD-1 FDA approved (September 2014) 2mg/kg q2W
– Advanced melanoma (post Ipilimumab and BRAFi if BRAF
mutant)
– Relatively well tolerated (fatigue pruritis and rash, 2 patients with
hepatitis, hypophysitis)
• Nivolumab
32
nivolumab in untreated melanoma w/o BRAF
mutation
Robert C et al. N Engl J Med 2015;372:320330
33
11
3/16/2015
Bladder Cancer: MPDL3280
PD-L1 tumor infiltrating
immune cells
ORR
Dx+ vs Dx- ORR
% (95% CI)
% (95% CI
IHC 3 (n=10)
50% (22-78)
43% (26-63)
IHC 2 (n = 20)
40% (21-64)
IHC 1 (n=23)
13% (4-32)
IHC 0 (n=12)
8% (0.4 -35)
11%(4-26)
 2 CRs (1 IHC 2, 1 IHC 3)
 16 of 17 responding pats had ongoing
responses at time of data cutoff
 ORR = 52% (95% CI, 32-70) for Dx+
with ≥ 12 weeks of f/u
Powles et al
ASCO 2014
Breakthrough therapy
designation by FDA
phase II started phase III planned
34
Kidney Phase I Nivo + Ipi
Hammers et al
ASCO 2014 35
Nivolumab: Hodgkins
36
12
3/16/2015
Cellular Therapy
• Heme. Chimeric antigen receptor (CAR) Modified TCells
– Targeting CD 19 (CLL, NHL,ALL and others)
– Leukopheresis, expose T cells to lentivirus …
• Nearly 50% RR in heavily treated patients
• Toxicity relatively well tolerated
– Reversible hepatotoxicity, renal toxicity
– Reversible tumor lysis syndrome
– B cell aplasia (toxicity or efficacy?)
• Supported with IVIG
• No excessive or frequent infections
– Cytokine release syndrome
David Porter
37
Therapeutic Cancer Vaccines
• Mechanism of action1
– Activation of T cells to
seek out and destroy
target cancer cells
Naive
T cell
Activated
APC
Activated
T cell
• Efficacy2,3
– Extended overall survival
in certain metastatic
diseases without an
effect on PFS
Normal
cells/tissue
Abnormal
cells/tissue
1. Drake CG. Nat Rev Immunol. 2010;10(8):580-593.
2. Kantoff PW, Schellhammer PF, et al. N Engl J Med. 2010;363(5):411-422.
3. Kantoff PW, Godfrey WR, et al. J Clin Oncol. 2010;28(7):1099-1105.
38
Preventive vs Therapeutic Vaccines
“Cancer treatment vaccines are designed to treat
cancers that have already developed. They are
intended to delay or stop cancer cell growth; to
cause tumor shrinkage; to prevent cancer from
coming back; or to eliminate cancer cells that
have not been killed by other forms
of treatment."
- NCI (2011)
National Cancer Institute. Cancer vaccines. http://www.cancer.gov/cancertopics/factsheet/Therapy/. Accessed December 15, 2012.
39
13
3/16/2015
Characteristics of Immunotherapy
ACTIVE
PASSIVE
Engages immune system
Enhances pre-existing immune
response
Durable
Short-lived
Some examples:
therapeutic cancer vaccines
Some examples:
mABs, cytokines
Rescigno M, Curigliano G, et al. Biochim Biophys Acta. 2007;1776(1):108-123.
40
Characteristics of Therapeutic Vaccines1,2
Therapeutic Vaccines
Target
Immune system
Response Kinetics
Delayed
Potential for Memory Response
Yes
Tumor Evolution Potential
New immunologic targets
Patient Considerations
Requires uncompromised immune
system (both systemically and at
tumor site)
Tolerable safety profile
1. Gulley JL. Hum Vaccin Immunother. 2013;9(1):1-3.
2. Slovin S. Clin Adv Hematol Oncol. 2012;10(2):90-100.
41
Program Agenda
Immune System’s Role in Cancer
Immunotherapy Landscape
Clinical Considerations of Immunotherapy
State of Immunotherapy
42
14
3/16/2015
Immunotherapy: Treatment Considerations
• Relative efficacy of immunotherapy may be greater
with lower tumor burden1,2
• Patient given immunotherapy earlier in disease
course might have a better outcome3
Tumor Growth Rate
†
†
†
Tumor Burden
B
Expected clinical outcome
if no treatment is provided
† Death
A
A Patient given a vaccine
earlier
B Patient given a vaccine
later
Time
Adapted with permission from Gulley JL, Drake CG.3
1. Kirkwood JM, Ferrone S, et al. CA Cancer J Clin. 2012;62(5):309-335.
2. Drake CG. Nat Rev Immunol. 2010;10(8):580-593.
3. Gulley JL, Drake CG. Clin Cancer Res. 2011;17(12):3884-3891.
43
Immunotherapy:
Treatment Considerations
• Standard practice in oncology is the use of
combination agents with different mechanisms
of action1-3
– Chemotherapy and mABs
– Radiation and chemotherapy
– Multiple chemotherapy regimens
• Immunotherapy offers potential for synergy with
other therapies1-6
1. Vermorken JB, Hitt R, et al. N Engl J Med. 2008;359(11):1116-1127. 4. Drake CG, Adler AJ, et al. Cancer Cell. 2005;7(3):239-249.
5. Mercader M, Kwon ED, et al. Proc Natl Acad Sci USA. 2001;98(25):14565-14570.
2. Slamon DJ, Norton L, et al. N Engl J Med. 2001;344(11):783-792.
6. Aragon-Ching JB, Gulley JL, et al. Front Biosci. 2007;12:4957-4971.
3. Gulley JL, Drake CG. Clin Cancer Res. 2011;17(12):3884-3891.
44
Program Agenda
Immune System’s Role in Cancer
Immunotherapy Landscape
Clinical Considerations of Immunotherapy
State of Immunotherapy
45
15
3/16/2015
Immunotherapy:
An Established Treatment Strategy
• More than a dozen different immunotherapy agents have
been approveda, with the majority over the last decade1-5
• Immunotherapy agents currently approved target >10
different cancer types1-5
FDA-Approved Immunotherapiesa
aNot
1.
2.
3.
4.
5.
Class
Approvals
Checkpoint inhibitor
2011, 2014
Therapeutic vaccine
2010
Monoclonal antibodies
1997, 1998, 2000, 2001, 2002, 2003,
2004, 2006, 2009
Cytokines
1986, 1992, 1995, 1998
inclusive of all immunotherapy classes.
Mellman I, Dranoff G, et al. Nature. 2011;480(7378):480-489.
Kirkwood JM, Ferrone S, et al. CA Cancer J Clin. 2012;62(5):309-335.
Lotze M. In: Cancer: Principles & Practice of Oncology. 9th ed. 2011.
Sondak VK, Hauschild A, et al. In: Cancer: Principles & Practice of Oncology. 9th ed. 2011.
Robinson MK, Weiner LM, et al. In: Cancer: Principles & Practice of Oncology. 9th ed. 2011.
46
Immunotherapy: Future Promise
• Rapid increase in immunotherapy
clinical research
– Doubling of abstracts at major
conferences from 2009 to 2012
– Approximately 800 clinical trials in
various phases ongoing
• eg, breast, colon, head and neck,
kidney
Courtesy of sciencephoto.com
• Trials utilize agents alone and in
combination with conventional therapies2
SeekingAlpha.com. http://seekingalpha.com/article/667581-immunotherapy-comes-of-age-at-asco-2012. Accessed January 4, 2013.
ClinicalTrials.gov. http://clinicaltrials.gov/. Accessed January 4, 2013.
47
HER2 targeted therapy
• Breast cancer historically not considered immune
responsive cancer
– HER2+ and TNBC may be exceptions
• Immune-related gene expression signatures
• Prognostic value of TILs
• High levels of TILs are associated with benefit to
trastuzumab and chemotherapy
Loi et al, 2013
Mahmoud et al, JCO 2011
48
16
3/16/2015
Summary
• The immune system plays a critical role in
controlling cancer1
• Key features of an effective immune response include2
– Specificity
– Adaptability
– Durability (immune memory)
• Future clinical considerations
– May elicit better immune system response if used earlier
in disease3,4
– Potential for durable clinical effects and synergy with
subsequent therapies5-8
1. Dunn GP, Schreiber RD , et al. Nat Rev Immunol. 2006;6(11):836-848.
2. Abbas AK, Lichtman AH. Basic Immunology. 3rd ed. 2011.
3. Kirkwood JM, Ferrone S, et al. CA Cancer J Clin. 2012;62(5):309-335.
4. Drake CG. Nat Rev Immunol. 2010;10(8):580-593.
5. Vermorken JB, Hitt R, et al. N Engl J Med. 2008;359(11):1116-1127.
6. Slamon DJ, Norton L, et al. N Engl J Med. 2001;344(11):783-792.
7. Robert C, Wolchok JD, et al. N Engl J Med. 2011;364(26):2517-2526.
8. Mercader M, Kwon ED, et al. Proc Natl Acad Sci USA. 2001;96(25):
14565-14570.
49
Questions?
MA-01.13.03.01
50
17